Overview

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Status:
RECRUITING

Trial end date:
2028-02-05

Target enrollment:

Participant gender:

Summary

To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Taichung Veterans General Hospital

Collaborators:

Chang Gung Memorial Hospital
China Medical University Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
National Cheng-Kung University Hospital
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan
Tri-Service General Hospital